Saddic Louis A, Chang Tzuu-Wang, Sigurdsson Martin I, Heydarpour Mahyar, Raby Benjamin A, Shernan Stanton K, Aranki Sary F, Body Simon C, Muehlschlegel Jochen D
Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts;
Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; and.
Physiol Genomics. 2015 Oct;47(10):455-62. doi: 10.1152/physiolgenomics.00049.2015. Epub 2015 Jul 14.
MicroRNAs (miRNAs) play a significant role in ischemic heart disease. Animal models of left ventricular (LV) ischemia demonstrate a unique miRNA profile; however, these models have limitations in describing human disease. In this study, we performed next-generation miRNA and mRNA sequencing on LV tissue from nine patients undergoing cardiac surgery with cardiopulmonary bypass and cardioplegic arrest. Samples were obtained immediately after aortic cross clamping (baseline) and before aortic cross clamp removal (postischemic). Of 1,237 identified miRNAs, 21 were differentially expressed between baseline and postischemic LV samples including the upregulated miRNAs miR-339-5p and miR-483-3p and the downregulated miRNA miR-139-5p. Target prediction analysis of these miRNAs was integrated with mRNA expression from the same LV samples to identify anticorrelated miRNA-mRNA pairs. Gene enrichment studies of candidate mRNA targets demonstrated an association with cardiovascular disease, cell death, and metabolism. Therapeutics that intervene on these miRNAs and their downstream targets may lead to novel mechanisms of mitigating the damage caused by ischemic insults on the human heart.
微小RNA(miRNA)在缺血性心脏病中发挥着重要作用。左心室(LV)缺血的动物模型显示出独特的miRNA谱;然而,这些模型在描述人类疾病方面存在局限性。在本研究中,我们对9例接受体外循环和心脏停搏心脏手术患者的LV组织进行了下一代miRNA和mRNA测序。样本在主动脉交叉钳夹后立即获取(基线)以及在主动脉交叉钳夹移除前获取(缺血后)。在1237个鉴定出的miRNA中,有21个在基线和缺血后LV样本之间差异表达,包括上调的miRNA miR-339-5p和miR-483-3p以及下调的miRNA miR-139-5p。对这些miRNA的靶标预测分析与来自相同LV样本的mRNA表达相结合,以鉴定反相关的miRNA-mRNA对。候选mRNA靶标的基因富集研究表明与心血管疾病、细胞死亡和代谢有关。干预这些miRNA及其下游靶标的治疗方法可能会产生减轻缺血性损伤对人类心脏造成损害的新机制。